Receptor antagonists or monoclonal antibodies targeting neutrophil-associated cytokines, such as IL-1R, IL-1β, and IL-6, could serve as valuable strategies for improving the clinical outcomes of COVID-19 treatment.524,525 Additionally, targeting NETs with recombinant human deoxyribonuclease (DNase) presents another potential therapeutic avenue.464 While further research is required, therapies directed at neutrophils hold promise as a viable approach for the effective treatment of COVID-19. This evidence concerns the gene IL1R1 and COVID-19.